Licensing Agreement For "Olutasidenib", An Acute Myeloid Leukemia Drug
04/09/2024 24:46
Kissei Pharmaceutical Co Ltd 4547.T :
* KISSEI PHARMACEUTICAL CO LTD - LICENSING AGREEMENT FOR
"OLUTASIDENIB", AN ACUTE MYELOID LEUKEMIA DRUG
Source text for Eikon: ID:nTSuc8db78
Further company coverage: 4547.T
Recent news on Rigel Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Berkshire Hathaway, Exxon Mobil, Honeywell Technologies
Rigel Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Rigel Pharmaceuticals Q2 revenue rises on strong product demand
Brief: Rigel Pharmaceuticals - Appoints Alison L. Hannah As Executive Vice President And Chief Medical Officer Effective July 1, 2026 - SEC Filing
Brief: Rigel Announces Closing Of Licensing Agreement For Veppanu (Vepdegestrant)